Clinical trials: Immune-related Adverse Events
HIV Infections
Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment
Subjects with HIV who have viral suppression on current regimen but also have side effects/intolerance will change their current regimen to a combination of Raltegravir and Atazanavir and be monitored for viral and immunological…
- Trial name
- NCT00751153
- Testing
- Raltegravir and Atazanavir
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Peter J. Ruane, M.D., Inc.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Liver Injury, Secondary to Immune Checkpoint Inhibitors
Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors.
- Conditions
- Liver Injury, Secondary to Immune Checkpoint Inhibitors, Cancer Patients
- Trial name
- CO-CHILI (NCT06864481)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer
MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy
This study aims to develop and evaluate a multidisciplinary team (MDT)-based nursing intervention system for patients with advanced small cell lung cancer (SCLC) receiving chemo-immunotherapy.
- Conditions
- Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Lung Neoplasms
- Trial name
- SCLC-MDT (NCT07489339)
- Testing
- Multidisciplinary Team-Based Nursing Intervention, Routine Nursing Care
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanxi Province Cancer Hospital
Melanoma Stage III or IV
CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
People who develop a type of skin cancer known as 'melanoma' are often treated with immunotherapy. The type of immunotherapy used for patients with melanoma is known as Immune Checkpoint Inhibitors (ICI).
- Trial name
- CARD-IO (NCT06605833)
- Testing
- 12-Lead ECG, Transthoracic Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive…
- Conditions
- Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity
- Trial name
- CARTIER (NCT03711110)
- Testing
- Intensive cardiovascular monitoring, No intervention
- Where
- 14 sites in Spain
- Volunteers
- 514 people
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Fatigue Symptom, Lymphoma Non-Hodgkin
Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
The incidence of cancer in 2023 is estimated at 433136 cases, according to INCa. Haemopathies account for 12% of these new cases of cancer cases of cancer, and around two-thirds are lymphoid haemopathies, in particular lymphomas.
- Conditions
- Fatigue Symptom, Lymphoma Non-Hodgkin, Chimeric Antigen Receptor T-cell Therapy, Adverse Events
- Trial name
- CAR-TIGUE (NCT06890091)
- Testing
- Fatigue assessment
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiotoxicity, Cancer
Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)
This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment.
- Conditions
- Cardiotoxicity, Cancer, Cardiac Arrhythmia, Left Ventricular Dysfunction
- Trial name
- NCT07776964
- Testing
- Mobile Cardiac Telemetry, Wearable Cardiac Monitor
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Minnesota
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Bullous Pemphigoid
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
The study is an observational, multi-center, prospective, non-interventional and open-label data collection study assessing outcomes, treatment patterns, adverse events and costs in patients diagnosed with bullous pemphigoid.
- Trial name
- EDP-PB (NCT02837965)
- Testing
- treatment with topical superpotent corticosteroid therapy, treatment with systemic therapy (methotrexate), treatment systemic therapy (prednisone)
- Where
- France
- Volunteers
- 149 people
- Sponsor
- CHU de Reims
Cancer, Immune-related Adverse Event
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
The purpose of this project is to collect body samples like blood and tissue and health information from people receiving immune-based treatment for cancer.
- Trial name
- IMBARC (NCT06089967)
- Testing
- Medical chart review
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Candidiasis, Esophageal, HIV Infections
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.
- Trial name
- NCT00005921
- Testing
- L-743,872
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypersensitivity Reactions
Post-market Safety Study of LUMISIGHT
This study is a prospective, multi-center, observational post-market safety study evaluating the incidence of anaphylaxis and hypersensitivity reactions associated with LUMISIGHT (pegulicianine) administration in adults with…
- Trial name
- NCT07572162
- Where
- 2 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Lumicell, Inc.
Immune-related Adverse Events, Advanced Solid Tumor
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use.
- Trial name
- NCT04375228
- Testing
- Rituximab, Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event
Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia
This is a retrospective biobank study evaluating the impact of novel genetic variants in a population of 6-mercaptopurine treated pediatric acute lymphoblastic leukemia patients.
- Trial name
- NCT04770922
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cipherome, Inc.
Any Advanced Solid Tumors
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the…
- Trial name
- IRIS (NCT07836101)
- Testing
- Sarilumab, ICI Therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Immune-Related Adverse Events
Study on Biomarkers of Immune-Related Adverse Events
1. To identify biomarkers of immune-related adverse events; 2. To develop a predictive model for immune-related adverse events.
- Trial name
- NCT07527585
- Volunteers
- 440 people
- Sponsor
- Huazhong University of Science and Technology
Systemic Lupus Erythematosus
A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
The purpose of this study is to compare the genotype-based personal prescription of cyclophosphamide with the traditional prescription.
- Trial name
- SLE (NCT01689350)
- Testing
- Genotype Detection
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Malignancy, Immune System Diseases
Immuno-Oncology Database and Bioregistry
Immunotherapy, especially immune checkpoint inhibitors (ICIs), are effective in treating many different types of cancers. ICIs fight cancer by driving the immune system into an "activated state" that makes it harder for tumor…
- Conditions
- Malignancy, Immune System Diseases, Autoimmune Diseases
- Trial name
- IOG (NCT04656873)
- Testing
- Biospecimen Collection, Medical Chart Review, Questionnaires/Surveys
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center